Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback